Quick Comparison

NMN (Nicotinamide Mononucleotide)SAMe
Half-Life2-3 minutes in blood (rapidly converted to NAD+). NAD+ half-life: 1-2 hours in tissue1.5-2 hours
Typical DosageStandard: 250-1000 mg daily. Sublingual may improve bioavailability by bypassing first-pass metabolism. Take in the morning — NAD+ follows circadian rhythm and morning supplementation aligns with natural peaks. Effects build over weeks.Standard: 400-1600 mg daily on an empty stomach. Start at 200-400 mg and increase gradually. Take in the morning — can be activating. Enteric-coated tablets preferred for stability. Often combined with B vitamins (B12, folate) which are needed for SAMe recycling.
AdministrationOral (capsules, powder, sublingual). Sublingual may improve bioavailability. Store in cool, dry place.Oral (enteric-coated tablets). Take on empty stomach 30 minutes before food. Enteric coating protects from stomach acid degradation.
Research Papers10 papers9 papers
Categories

Mechanism of Action

NMN (Nicotinamide Mononucleotide)

NMN is transported into cells via the Slc12a8 transporter (highly expressed in the small intestine and brain) and converted to NAD+ by nicotinamide mononucleotide adenylyltransferases (NMNAT1 in the nucleus, NMNAT2 in axons/Golgi, NMNAT3 in mitochondria). Elevated NAD+ activates the sirtuin family of NAD+-dependent protein deacetylases: SIRT1 deacetylates PGC-1alpha to promote mitochondrial biogenesis, SIRT3 activates superoxide dismutase 2 (SOD2) and isocitrate dehydrogenase 2 (IDH2) for mitochondrial antioxidant defense, and SIRT6 promotes base excision repair of oxidative DNA damage. NAD+ is also consumed by poly(ADP-ribose) polymerases (PARP1/2) during DNA repair — age-related NAD+ depletion impairs PARP function, allowing DNA damage accumulation. In neurons, NAD+ is required for glycolysis (GAPDH cofactor), the TCA cycle, and Complex I of the electron transport chain, directly fueling the enormous ATP demands of synaptic transmission. NAD+ decline with aging (approximately 50% reduction between ages 40-60) reduces all of these processes simultaneously, creating a cascade of mitochondrial dysfunction, impaired DNA repair, and neuroinflammation that NMN supplementation aims to reverse.

SAMe

SAMe serves as the principal methyl donor in over 100 transmethylation reactions catalyzed by SAM-dependent methyltransferases. In the brain, it donates methyl groups to phosphatidylethanolamine N-methyltransferase (PEMT), converting PE to phosphatidylcholine and maintaining neuronal membrane fluidity critical for receptor function. It methylates DNA via DNMT enzymes, modulating gene expression epigenetically. SAMe is essential for catechol-O-methyltransferase (COMT) activity, which metabolizes dopamine and norepinephrine, and for phenylethanolamine N-methyltransferase (PNMT), which converts norepinephrine to epinephrine. It feeds the transsulfuration pathway, producing cysteine via cystathionine beta-synthase (CBS) and cystathionine gamma-lyase, ultimately supporting glutathione synthesis for antioxidant defense. SAMe also donates methyl groups for myelin basic protein methylation, essential for myelin sheath integrity and nerve conduction velocity.

Risks & Safety

NMN (Nicotinamide Mononucleotide)

Common

Mild flushing, nausea, headache initially.

Serious

Long-term human safety data still limited (first human trials completed 2020-2023). Theoretical concern about promoting cancer growth in existing tumors (NAD+ fuels fast-growing cells).

Rare

Insomnia if taken late.

SAMe

Common

Nausea, diarrhea, anxiety, insomnia.

Serious

Can trigger manic episodes in bipolar disorder. Serotonin syndrome risk when combined with SSRIs or MAOIs.

Rare

Skin rash, increased homocysteine without B vitamin co-supplementation.

Full Profiles